Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Certolizumab pegol
UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia
Medicine Registered
1 of 25 NAME OF THE MEDICINE Cimzia ® (certolizumab pegol) CIMZIA 200 mg/mL Injection. Chemical structure: _CH_ _ _ _3_ _ _ _O(CH_ _ _ _2_ _ _ _CH_ _ _ _2_ _ _ _O)_ _ _ _N_ _ _ _CONH_ _ _ _CONH_ _ _ _NH_ _ _ _N_ _ _ _CH_ _ _ _3_ _ _ _O(CH_ _ _ _2_ _ _ _CH_ _ _ _2_ _ _ _O)_ _ _ _N_ _ _ _CONH_ _ _ _O_ _ _ _O_ _ _ _O_ _ _ _S_ _ _ PEG FAB' N = ~450 Chemical Name: gHTNF40 Fab'40 kDa PEG MW: approximately 90,000 Da CAS number: [428863-50-7] DESCRIPTION Certolizumab pegol is a recombinant, humanised antibody Fab' fragment that is expressed in an _Escherichia coli_ bacterial expression system, subsequently purified and conjugated to polyethylene glycol (PEG). _200 MG/ML INJECTION IN A SINGLE-USE PRE-FILLED SYRINGE _ Cimzia ® injection is a sterile clear to opalescent solution that is colourless to yellow, essentially free of visible particles, containing 200 mg certolizumab pegol per mL. The inactive ingredients are sodium chloride, sodium acetate and water for injections. The pH of the solution is approximately 4.7. PHARMACOLOGY MECHANISM OF ACTION Certolizumab pegol has a high affinity for human TNFα and binds with a dissociation factor (K D ) of 90pM. TNFα is a key pro-inflammatory cytokine with a central role in inflammatory processes. Certolizumab pegol selectively neutralises TNFα (90% inhibitory concentration [IC 90 ]) of 4 ng/mL for inhibition of human TNFα in the _in vitro_ L929 murine fibrosarcoma cytotoxicity assay) but does not neutralise lymphotoxin α (TNFβ). Certolizumab pegol cross-reacts poorly with TNF from rodents and rabbits, therefore _in vivo_ efficacy was evaluated using animal models in which human TNFα was the physiologically active molecule. Certolizumab pegol was shown to neutralise membrane Read the complete document